TORI MARTIN: Open Payments
NPI 1396383980 · SYRACUSE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$737 in 37 payments from 12 companies in 2025. Trend: 2023 $687 · 2024 $340 · 2025 $737
Food & beverage: $737
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $250 |
| ABBVIE INC. | 8 | $146 |
| Biogen, Inc. | 3 | $60 |
| Lundbeck LLC | 2 | $52 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Janssen Pharmaceuticals, Inc | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
Products named: CAPLYTA, VRAYLAR, REXULTI, ZURZUVAE, COBENFY, Auvelity, INVEGA, INGREZZA.
Industry payments across NY — which companies pay providers there.
